OBJECTIVES: To report the functional and oncological outcomes of @entity263 using the Ablatherm Integrate Imaging(  ) device. METHODS: Between January 2005 and June 2009, all @entity1 treated with HIFU as a primary care option for @entity263 and fulfilling the French Urological Association (AFU) guideline were included in this study. Validated questionnaires were used to assess continence, potencies and quality of life. RESULTS: A total of 297 @entity1 met the inclusion criteria: 149 were low risk and 148 were intermediate risk according to d'Amico's risk group. The median @entity1486 (PSA) nadir was 0.12ng/ml with 65% of @entity1 reaching a nadir less than 0.3  ng/ml. Systematic control biopsies were performed on 175 @entity1 with 89% of negative biopsies. The disease free survival rate at 40 months was 79% for low risk group and 62% for intermediate risk group. The pre and post-HIFU treatment International Prostate Symptoms Score (IPSS) score and quality of life questionnaire were not statistically different. In the opposite, the pre and post-HIFU erection function and continence status were significantly different. CONCLUSION: Local control and Biochemical Free Survival Rate achieved with HIFU were similar to those expected with conformal external radiation beam therapy. Among the functional outcomes, potency was the most impacted by the treatment.

[Outcomes of HIFU for XXXX using the Ablatherm Integrate Imaging   device].

@entity1 :: ('9606', 'Species') :: ['patients'] @entity263 :: ('MESH:D011471', 'Disease') :: ['localized prostate cancer', 'HIFU for prostate cancer'] @entity1486 :: ('354', 'Gene') :: ['prostate specific antigen']
@entity263 :: (MESH:D011471,Disease) :: ['localised prostate cancer']
